Hyperacute transplantation of umbilical cord mesenchymal stromal cells in a model of severe intracerebral hemorrhage

AIM: Intracerebral hemorrhage (ICH) has limited therapeutic options. We have shown that an intravenous injection of human umbilical cord-derived mesenchymal stromal cells (hUC-MSC) 24 h after an ICH in rats reduced the residual hematoma volume after a moderate hemorrhage but was inefficient in sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Mello, Tanira Giara, Rosado-de-Castro, Paulo Henrique, Vasques, Juliana Ferreira, Pinhão, Carolina, Santos, Tayná Monteiro, de Lima, Renata Rodrigues, Foerster, Bernd Uwe, Paiva, Fernando Fernandes, Mendez-Otero, Rosalia, Pimentel-Coelho, Pedro Moreno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965815/
https://www.ncbi.nlm.nih.gov/pubmed/35369279
http://dx.doi.org/10.2144/fsoa-2021-0121
Descripción
Sumario:AIM: Intracerebral hemorrhage (ICH) has limited therapeutic options. We have shown that an intravenous injection of human umbilical cord-derived mesenchymal stromal cells (hUC-MSC) 24 h after an ICH in rats reduced the residual hematoma volume after a moderate hemorrhage but was inefficient in severe ICH. Here, we investigated whether a treatment in the hyperacute phase would be more effective in severe ICH. MATERIALS & METHODS: Wistar rats were randomly selected to receive an intravenous injection of hUC-MSC or the vehicle 1 h after a severe ICH. RESULTS: The hyperacute treatment with hUC-MSC did not affect the 22-day survival rate, the motor function or the residual hematoma volume. CONCLUSION: These results indicate the need for optimization of hUC-MSC-based therapies for severe ICH.

Ejemplares similares